In order to continue building brand awareness regarding its chat with a doctor program, MD247 announced a social media contest in which it would be awarding $1,000.00 to the 5,000th person to like the MD247 Facebook page.
Tampa Florida (PRWEB) January 01, 2013
In order to continue building brand awareness regarding its chat with a doctor program, MD247 announced a social media contest in which it would be awarding $1,000.00 to the 5,000th person to like the MD247 Facebook page. The winner will be determined using a record of all likes provided to the parties responsible for the administration of the MD247 business page on the social media platform. The $1,000.00 will be split equally between the 5,000th person to like the MD247 Facebook page, and the friend who referred that person to the MD247 Facebook page.
The MD247 social media team will be making frequent posts to initially build interest in the prize, and the contest will eventually be shared on a daily basis. The contest will be running December 24, 2012 through 03/01/2013, and MD247 is allowing both employees and anyone else interested in the MD247 program to participate in the contest.
All parties interested in participating in the MD247 contest for $1,000.00 should visit the MD247 Facebook business page at http://www.facebook.com/md247dotcom.
Seminole Florida based MD247 (MD 247; MD/247; M.D. 247; MD247.COM) provides discounted telemedicine healthcare services nationwide to families, and discounted wholesale telemedicine healthcare to businesses. MD247 has successfully provided 25,000 people the ability to chat with a doctor twenty-four hours a day, talk to a nurse twenty-four hours a day, receive discounted prescription drugs and receive discounted in-person healthcare services. In addition to discounted healthcare services, MD247 provides support to groups supporting the employment of veterans of the United States Armed Services. MD247 services, as well as informational blogs, can be found for review online at http://www.md247.com.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/1/prweb10281854.htm
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.